GlassScriptPhysician profile
Geethanjali Ramamurthy
NPI 1093707887
$2,481.44
in general payments reported to CMS, 2019-2025
24 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $384 · 2021: $153 · 2022: $460 · 2023: $301 · 2024: $400 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $524.53 | 2019-2023 | Krystexxa |
| Amgen INC. | $438.96 | 2024-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $224.95 | 2019-2024 | Farxiga |
| Travere Therapeutics, INC. | $172.17 | 2022-2024 | |
| Glaxosmithkline, LLC. | $125.64 | 2020-2024 | Benlysta |
| Mallinckrodt Enterprises LLC | $122.07 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $119.97 | 2019-2020 | |
| Vifor Pharma, INC. | $100.31 | 2022-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $92.76 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.02 | 2021-2023 | |
| Akebia Therapeutics INC | $77.71 | 2019-2025 | Vafseo, Auryxia |
| Baxter Healthcare | $59.56 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $49.58 | 2021-2025 | Lupkynis |
| Shire North American Group INC | $47.55 | 2019 | |
| Novo Nordisk INC | $37.00 | 2025 | Ozempic |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $35.81 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.48 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $26.34 | 2022 | |
| Recor Medical INC | $21.37 | 2024 | Paradise Renal Denervation System |
| Alexion Pharmaceuticals, INC. | $20.11 | 2022 | |
| Ani Pharmaceuticals, INC. | $19.70 | 2023 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $19.57 | 2025 | Terlivaz |
| Daiichi Sankyo INC. | $15.91 | 2019 | |
| Cook Medical LLC | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geethanjali Ramamurthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.